STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
T
Recruiting
- Thrombocythemia, Essential
- San Antonio, TexasMays Cancer Center
2021-12-14
Dec 14, 2021U
Completed
- Atherosclerosis
- imaging
- (no location specified)
2021-10-06
Oct 6, 2021I
Recruiting
- Essential Thrombocytopenia
- Recombinant Interferon Alpha
- Pegylated interferon alfa-2b
- Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
2022-03-25
Mar 25, 2022I
Recruiting
- Thrombocythemia, Essential
- Primary Myelofibrosis
- Hong Kong, Hong KongQueen Mary Hospital
2022-01-24
Jan 24, 2022T
Recruiting
- Essential Thrombocythemia
- Polycythemia Vera
- Miami, FloridaUniversity of Miami
2021-09-23
Sep 23, 2021D
Completed
- Polycythemia Vera
- Thrombocythemia, Essential
- No cytoreductive vs cytoreductive drugs
- Geneva, Switzerland
- +1 more
2020-11-09
Nov 9, 2020U
Recruiting
- CALR Gene Mutation
- +5 more
- Continuous Positive Airway Pressure
- +2 more
- Salt Lake City, UtahHuntsman Cancer Institute/University of Utah
2022-03-01
Mar 1, 2022F
U
Active, not recruiting
- Myeloproliferative Neoplasm
- +4 more
- Orange, CaliforniaChao Family Comprehensive Cancer Center, University of Californi
2022-01-20
Jan 20, 2022M
Not yet recruiting
- Myelofibrosis
- +2 more
- Peptide-based vaccine
- Poly ICLC
- New York, New YorkIcahn School of Medicine at Mount Sinai
2021-08-24
Aug 24, 2021M
Not yet recruiting
- Essential Thrombocythemia
- Polycythemia Vera
- Boston, Massachusetts
- +2 more
2020-11-24
Nov 24, 2020S
Completed
- Essential Thrombocythaemia
- anagrelide hydrochloride
- Barcelona, Spain
- +4 more
2021-06-07
Jun 7, 2021N
Not yet recruiting
- Primary Myelofibrosis
- +2 more
- NS-018
- Best Available Therapy
- (no location specified)
2021-11-05
Nov 5, 2021N
Active, not recruiting
- Primary Myelofibrosis
- +2 more
- Jakavi
- Aachen, GermanyNovartis Investigative Site
2021-09-06
Sep 6, 2021U
Not yet recruiting
- Myeloproliferative Neoplasm
- +3 more
- CALR allele burden quantification
- (no location specified)
2021-06-18
Jun 18, 2021J
Active, not recruiting
- Primary Myelofibrosis
- +4 more
- New York, New YorkIcahn School of Medicine at Mount Sinai
2021-05-19
May 19, 2021M
Recruiting
- Myelofibrosis Transformation in Essential Thrombocythemia
- +2 more
- Elotuzumab
- Questionnaire Administration
- Houston, TexasM D Anderson Cancer Center
2021-02-17
Feb 17, 2021H
Unknown status
- Essential Thrombocythemia
- +2 more
- Diagnostic (18F-FLT PET/CT)
- Doha, QatarNational Center for Cancer Care & Research (NCCCR)
2020-09-27
Sep 27, 2020L
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Farmington Hills, Michigan
- +1 more
2021-06-05
Jun 5, 2021U
Recruiting
- Primary Myelofibrosis
- +2 more
- Salt Lake City, UtahHuntsman Cancer Institute/University of Utah
2021-09-27
Sep 27, 2021S
Recruiting
- Myelofibrosis
- +3 more
- Jaktinib hydrochloride tablets
- Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical School of Zhejiang Univ
2021-06-11
Jun 11, 2021S
Completed
- Primary Myelofibrosis
- +4 more
- Scottsdale, Arizona
- +21 more
2021-01-18
Jan 18, 2021N
M
Active, not recruiting
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- +2 more
- Laboratory Biomarker Analysis
- +2 more
- Houston, TexasM D Anderson Cancer Center
2021-11-08
Nov 8, 2021M
Recruiting
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- +3 more
- Azacitidine
- +2 more
- Houston, TexasM D Anderson Cancer Center
2021-10-30
Oct 30, 2021